Latest filings (excl ownership)
8-K
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
10 Jan 25
8-K
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
2 Jan 25
8-K
Termination of a Material Definitive Agreement
8 Nov 24
8-K
Immunocore reports third quarter financial results and provides a business update
6 Nov 24
10-Q
2024 Q3
Quarterly report
6 Nov 24
8-K
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
16 Sep 24
8-K
Immunocore announces transition of Chief Financial Officer
29 Aug 24
8-K
Immunocore reports second quarter financial results and provides a business update
8 Aug 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
8-K
Regulation FD Disclosure
31 May 24
8-K
Other Events
30 May 24
8-K
Entry into a Material Definitive Agreement
28 May 24
8-K
Submission of Matters to a Vote of Security Holders
23 May 24
8-K
Immunocore reports first quarter financial results and provides a business update
8 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
8-K
Other Events
5 Apr 24
424B7
Prospectus with selling stockholder info
5 Apr 24
PRE 14A
Preliminary proxy
2 Apr 24
S-8
Registration of securities for employees
20 Mar 24
S-3ASR
Automatic shelf registration
20 Mar 24
8-K
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Immunocore Prices Upsized Convertible Senior Notes Offering
2 Feb 24
8-K
Immunocore Announces Proposed Convertible Senior Notes Offering
29 Jan 24
8-K
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
5 Jan 24
8-K
Regulation FD Disclosure
2 Jan 24
6-K
Current report (foreign)
7 Nov 23
6-K
Current report (foreign)
10 Aug 23
6-K
Current report (foreign)
14 Jul 23
6-K
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
5 Jun 23
6-K
Current report (foreign)
16 May 23
6-K
Current report (foreign)
10 May 23
6-K
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
18 Apr 23
6-K
Current report (foreign)
18 Apr 23
S-8
Registration of securities for employees
6 Apr 23
6-K
Current report (foreign)
10 Mar 23
6-K
Current report (foreign)
2 Mar 23
20-F
2022 FY
Annual report (foreign)
1 Mar 23
Latest ownership filings
4
Leger Tina Amber St
19 Feb 25
4
JOHN GOLL
19 Feb 25
4
David M Berman
19 Feb 25
4
Bahija Jallal
19 Feb 25
SC 13G
Jallal Bahija
14 Feb 25
SC 13G
PRIMECAP MANAGEMENT CO/CA/
13 Feb 25
4
Travis Alan Coy
3 Jan 25
SC 13G/A
T. Rowe Price Investment Management, Inc.
14 Nov 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Nov 24
SC 13G/A
RTW INVESTMENTS, LP
14 Nov 24
SC 13G/A
Rock Springs Capital Management LP
12 Nov 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Nov 24
SC 13G
T. Rowe Price Investment Management, Inc.
10 Sep 24
4
JULIAN BAKER
29 May 24
3
RANJEEV KRISHANA
29 May 24
3
JULIAN BAKER
29 May 24
4
Siddharth Kaul
28 May 24
4
Peter John Ratcliffe
28 May 24
4
Kristine Peterson
28 May 24
4
Roy Steven Herbst
28 May 24
4
John Irving Bell
28 May 24
4
Leger Tina Amber St
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
SC 13G
FMR LLC
11 Mar 24
SC 13D/A
GENERAL ATLANTIC, L.P.
7 Mar 24
4
David M Berman
1 Mar 24
4
David M Berman
28 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
4
Leger Tina Amber St
21 Feb 24
4
Donato Brian Di
21 Feb 24
4
JOHN GOLL
21 Feb 24
4
David M Berman
21 Feb 24
4
Bahija Jallal
21 Feb 24
SC 13G/A
Rock Springs Capital Management LP
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 24
SC 13D/A
BAKER BROS. ADVISORS LP
1 Feb 24
4
Leger Tina Amber St
5 Jan 24